Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration

The Cystic Fibrosis Transmembrane Conductance Regular (CFTR) modulator, a combination of elexacaftor, tezacaftor, and ivacaftor (ETI, TRIKAFTA ®), has led to significant improvements in lung function in people with cystic fibrosis (pwCF) [1] [2,3],. However, the concomitant use of strong CYP3A inducers such as rifampin and rifabutin is not recommended since all three components of ETI are primarily eliminated through cytochrome P450 (CYP) 3A-mediated hepatic metabolism [4,5]. A previous pharmacokinetic (PK) study has shown that co-administration of rifampin significantly decreases the area-under-the concentration-time curve (AUC) of ivacaftor by 89 % (AUC ratio of 0.11) [6]
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Short Communication Source Type: research